Navigation Links
SynCo Bio Partners Enters the Japanese Market as it Signs its First Agreement With a Japanese Pharmaceutical Company
Date:9/1/2009

AMSTERDAM, September 1 /PRNewswire/ -- SynCo Bio Partners B.V., the expert in long term GMP contract manufacturing of biopharmaceuticals announced today that it has expanded its business into a new geographical market, with the signing of a contract to manufacture a live biotherapeutic for an emerging Japanese pharmaceutical company.

The undisclosed company's product is an innovative live biotherapeutic based anticancer drug. The project will first involve a consultancy phase, during which SynCo will assist the client with in-house process development. The developed process will then be transferred to SynCo's Amsterdam facility and scaled-up, prior to GMP manufacture for Phase I clinical trials, including fermentation, formulation and aseptic filling.

"We are extremely pleased to be working with our first Japanese partner," commented SynCo's CEO, Mr. Pierre Warffemius, "this is an exciting project for a leading Japanese business and I look forward to the successful completion of GMP manufacture, in the field of live biotherapeutics. This contract represents SynCo's entry into the growing Japanese biotherapeutics market and is reflective of our continuing success in a very competitive GMP contract manufacturing market."

SynCo is a specialist in the development of manufacturing processes and GMP production of live biotherapeutics and provides a one-stop-shop for the production of both bulk drug substance and final lyophilized product. This project is one of a rapidly growing number SynCo is involved with in this field.

For more information, please visit http://www.syncobiopartners.com

About SynCo Bio Partners B.V.

SynCo Bio Partners is a GMP-licensed bulk drug substance and final product CMO with clinical and commercial production experience with mammalian and microbial systems. This experience has been acquired by developing new production processes for a number of international clients and producing a wide variety of different vaccines, live bacterial products and recombinant proteins in our state-of-the-art, GMP-licensed facilities since inception in 2000.

Focused solely on biopharmaceuticals, SynCo Bio Partners acts as a strategic, long-term partner delivering product on time to the highest quality standards. SynCo 's team are committed to exceeding customer expectations taking a truly collaborative approach to manufacturing.

http://www.syncobiopartners.com


'/>"/>
SOURCE SynCo Bio Partners B.V.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. SynCo Bio Partners to Manufacture Versartis Novel Drug for Type 2 Diabetes
2. SynCo Bio Partners Increases its Capacities by Expanding its Quality Team
3. SynCo Bio Partners Wins Best Contract Manufacturing Organization 2009 ViE Award
4. SynCo Bio Partners Completes Manufacture and Release of ActoGeniX Lead Product for Phase II Clinical Trials
5. OmniComm Systems Inc. Expands Its Successful CRO Preferred Program(TM) By Signing On Three New CRO Partners
6. Masimo to Present at the Thomas Weisel Partners Healthcare Conference 2009
7. AutoGenomics Invited to Present at Thomas Weisel Partners 2009 Healthcare Conference
8. MEDRAD Partners with the University of South Florida and Moffitt Cancer Center to Study Workflow and Process Improvements in PET Imaging
9. Health Robotics Receives Overwhelming Support from its Customers for its McKesson-CytoCare Partnership
10. Cryo-Cell Announces Strategic Partnership With S-Evans Biosciences, Inc.
11. Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2017)... ... July 17, 2017 , ... Neurodevelopmental ... wide range of overlapping clinical features. The advancement of targeted next-generation sequencing (NGS) ... NDD research and testing. , However, designing a custom panel for disease ...
(Date:7/17/2017)... ... July 17, 2017 , ... Co-Diagnostics, Inc. (NASDAQ: ... intends both to manufacture and sell reagents used for diagnostic tests, has completed ... Headquartered in Sandy, Utah, Co-Diagnostics’ intellectual property and technologies are protected by five ...
(Date:7/16/2017)... N.J. (PRWEB) , ... July 16, 2017 , ... ... laboratory equipment and analytical instruments announced the launch of its new line of ... introduced five rocking and waving shaker models (both analog and digital) for laboratory ...
(Date:7/15/2017)... ... July 15, 2017 , ... Cuvette manufacturer FireflySci has been making ... the people at FFS have learned that their biggest asset was their amazing customer ... to launch new products to meet the changing needs of scientists at a rapid ...
Breaking Biology Technology:
(Date:6/23/2017)... N.Y. and ITHACA, N.Y. ... ) and Cornell University, a leader in dairy research, ... with bioinformatics designed to help reduce the chances that ... With the onset of this dairy project, Cornell University ... Consortium for Sequencing the Food Supply Chain, a food ...
(Date:5/16/2017)... 16, 2017  Veratad Technologies, LLC ( www.veratad.com ), ... and identity verification solutions, announced today they will participate ... May 15 thru May 17, 2017, in ... Trade Center. Identity impacts the lives ... today,s quickly evolving digital world, defining identity is critical ...
(Date:4/24/2017)... , April 24, 2017 ... and partner with  Identity Strategy Partners, LLP (IdSP) ... "With or without President Trump,s March 6, 2017 ... Terrorist Entry , refugee vetting can be instilled with ... resettlement. (Right now, all refugee applications are suspended ...
Breaking Biology News(10 mins):